ACIP: Recommends Resuming Use of Janssen COVID-19 Vaccine

Hello,

As part of our ongoing commitment to share important decisions and recommendations with you, below is a summary of today’s Advisory Committee on Immunization Practices (ACIP) meeting and subsequent vote. 

The ACIP met today, April 23, to discuss and vote on updated recommendations for the Janssen COVID-19 vaccine. The ACIP members received updates on thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 vaccine. The members then used the Evidence to Recommendation Framework to develop a recommendation. 

Recommendations

The committee members voted to recommend lifting the pause on the Janssen COVID-19 vaccine. The official recommendation from ACIP is “The Janssen COVID-19 vaccine is recommended for persons 18 years of age and older in the U.S. population under the FDA’s Emergency Use Authorization.” The ACIP recommendation will go to the CDC Director and CDC will issue specific recommendations based on the ACIP vote. A Morbidity and Mortality Weekly Report will be published on Tuesday, April 27 along with clinical guidance and accompanying materials. 

The recommendation should be implemented in the context of current CDC allocation recommendations. 

Background

On April 13, CDC sent a message via the Health Alert Network about recent cases of cerebral venous sinus thrombosis with thrombocytopenia in individuals after receiving the Janssen COVID-19 vaccine. CDC recommended that clinicians pause the use of the Janssen COVID-19 vaccine until the ACIP could meet to further review the cases and assess their potential significance. For more information about the cases, please see the CDC Health Alert Network from April 13, 2021. The ACIP met on April 14 to learn about the cases and discuss policy options. After a very thorough conversation, the committee agreed to continue the pause on vaccination with the Janssen COVID-19 vaccine until they could review additional data. Today’s meeting allowed for review of the additional information needed for the workgroup to make a recommendation.

Thank you.

 


American Immunization Registry Association 1717 Pennsylvania Avenue NW, Suite 1025, Washington, District of Columbia 20006, United States 202.522.0208
image